Answers are grounded in this paper and cite their sources.
S5. Targeting Polθ + PARP1 and Polθ + RAD52 induced dual synthetic lethality against HR-deficient leukemia cells.
No takes yet. Share an insight, caveat, or question.
Sullivan-Reed et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: